E. Ohman J or Asset Management AB Increases Stock Holdings in Gilead Sciences, Inc. $GILD

E. Ohman J or Asset Management AB raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 22.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 396,125 shares of the biopharmaceutical company’s stock after purchasing an additional 71,478 shares during the period. Gilead Sciences accounts for 1.1% of E. Ohman J or Asset Management AB’s investment portfolio, making the stock its 16th biggest position. E. Ohman J or Asset Management AB’s holdings in Gilead Sciences were worth $48,620,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Trivium Point Advisory LLC raised its position in Gilead Sciences by 1.1% during the third quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock valued at $813,000 after purchasing an additional 83 shares in the last quarter. Binnacle Investments Inc increased its stake in shares of Gilead Sciences by 11.8% in the third quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company’s stock worth $87,000 after buying an additional 83 shares during the period. Hemington Wealth Management raised its stake in shares of Gilead Sciences by 9.3% during the third quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 85 shares during the last quarter. Ignite Planners LLC raised its position in Gilead Sciences by 1.1% during the 3rd quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock valued at $880,000 after purchasing an additional 86 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. lifted its stake in Gilead Sciences by 0.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 34,711 shares of the biopharmaceutical company’s stock worth $3,912,000 after acquiring an additional 87 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total transaction of $617,500.00. Following the completion of the transaction, the director owned 8,920 shares in the company, valued at approximately $1,101,620. This trade represents a 35.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the transaction, the chief executive officer directly owned 642,308 shares of the company’s stock, valued at approximately $92,999,775.32. This trade represents a 1.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 309,280 shares of company stock worth $44,068,850. 0.27% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. HSBC upped their target price on Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a report on Wednesday, December 10th. Daiwa Securities Group lifted their target price on Gilead Sciences from $129.00 to $161.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Bank of America set a $162.00 target price on Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, February 11th. Deutsche Bank Aktiengesellschaft boosted their price objective on Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $170.00 price target on shares of Gilead Sciences in a report on Monday, February 23rd. Twenty-four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $157.62.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Acquisition adds OM336 (gamgertamig), a BCMAxCD3 T‑cell engager designed for rapid, deep B‑cell depletion—strengthens Gilead’s inflammation/autoimmune pipeline and provides a near‑term clinical asset that could drive future revenue if successful. Gilead Sciences to Acquire Ouro Medicines (Business Wire)
• Positive Sentiment: Major media and wire coverage confirms deal size and strategic rationale, increasing market confidence around the transaction’s credibility and near‑term impact. Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion (WSJ) Gilead to buy biotech firm Ouro Medicines in over $2 billion deal (Reuters)
• Positive Sentiment: Analyst support: Bank of America maintained a Buy rating and $162 price target, citing HIV franchise momentum and product upside—analyst backing can bolster investor sentiment. Buy Rating on Gilead (TipRanks / BofA)
• Neutral Sentiment: Health care sector strength is supporting stocks broadly, providing incidental tailwinds to GILD alongside the M&A news. Gilead nears up to $2bn deal for autoimmune biotech (Yahoo Finance)
• Neutral Sentiment: Reported March short‑interest data appear anomalous (showing zero/share changes and NaN), suggesting no clear short‑position signal from the data release. No reliable market pressure evident from short interest.
• Negative Sentiment: Deal and clinical risk: the price (up to $2.18B) is material and the asset is clinical‑stage—clinical trial failure, integration costs, or disappointments on OM336’s commercial potential could weigh on the stock. Gilead nearing up to $2 billion buyout of Ouro Medicines (Reuters)

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $137.34 on Tuesday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The company has a 50 day moving average price of $142.98 and a 200-day moving average price of $128.15. The company has a market capitalization of $170.50 billion, a PE ratio of 20.29, a P/E/G ratio of 1.80 and a beta of 0.36. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. Gilead Sciences’s revenue was up 4.7% compared to the same quarter last year. During the same period last year, the company posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be issued a $0.82 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s dividend payout ratio is 48.45%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.